NEW YORK (TheStreet) --aAlcobra shares are down -2.81% to $20.03 on Wednesday after having coverage initiated with a "market perform" rating and $23 price target by analysts at FBR Capital Markets. The Israel-based biopharmaceutical company is in the process of developing a drug treatment for Attention Deficit Hyperactivity Disorder. Must Read: Warren Buffett's 25 Favorite Stocks STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. a ADHD data by YCharts EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.
Click to view a price quote on ADHD. Click to research the Drugs industry.
from Latest TSC Headlines http://ift.tt/1tc7ErB
No comments:
Post a Comment